To evaluate efficacy of Bacillus calmette-guerin (Bcg) in reducing the incidence & severity of Covid-19 in the high-risk population (Bric)- A Phase III, multicentric, quadruple blind randomized controlled trial | India Science, Technology & Innovation - ISTI Portal

×

Acces sibility Controls

To evaluate efficacy of Bacillus calmette-guerin (Bcg) in reducing the incidence & severity of Covid-19 in the high-risk population (Bric)- A Phase III, multicentric, quadruple blind randomized controlled trial

Implementing Organization

All India Institute of Medical Sciences

Principal Investigator

Prof. S. Sinha All India Institute of Medical Sciences Delhi

Related Research

Quick Information

Area of Research

Medical Sciences

Focus Area

Task Force (TF)

Start Year

2020

End Year

2021

Duration

24

Sanction Amount

₹ 2.01 Cr

Status

Completed

Output

No. of Research Paper

00

Technologies (If Any)

00

No. of PhD Produced

00

No. of Patents

Filed : 00

Grant : 00

Disclaimer: Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.

Latest Updates

Loading…